File(s) not publicly available
Pentavalent rotavirus vaccine (RotaTeq®) in the prevention of rotavirus gastroenteritis in the EU: a profile of its use
online resourceposted on 21.03.2018, 02:46 by Yahiya Y. Syed, Katherine A. Lyseng-Williamson
Compliance with ethical standards
Funding: The preparation of this review was not supported by any external funding.
Conflicts of interest: Y.Y. Syed and K.A. Lyseng-Williamson are employees of Adis/Springer, are responsible for the article content and declare no conflicts of interest.
Additional information about this Adis Drug Review can be found here.
RotaTeq® is a three-dose, pentavalent, human-bovine reassortment vaccine, indicated for the prevention of rotavirus gastroenteritis (RVGE) in infants aged 6–32 weeks in the EU. The vaccine solution is given orally and can be administered with a number of common childhood vaccines. In the pivotal REST study, RotaTeq® showed high protective efficacy with respect to reductions in the RVGE incidence and associated hospitalizations or emergency department visits. The effectiveness and impact of the vaccine against RVGE-related healthcare use were demonstrated in several real-world studies. RotaTeq® was generally well tolerated, with no or minimal risk of intussusception. Access to the full article can be found here.
© Springer International Publishing AG, part of Springer Nature 2018